Optimind Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma
Optimind Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma
Manitari Pharma received approval to begin construction of Security Level 3 safe plus grow rooms, Manitari Pharma is one step closer to obtaining Controlled Substances Dealer's Licence for Psilocybin Research
Manitari Pharma獲得批准開始建設安全級別3的安全加長室Manitari Pharma距離獲得裸蓋菇素研究受控物質經銷商許可證又近了一步
Toronto, Ontario--(Newsfile Corp. - August 10, 2022) - Optimind Pharma Corp. (CSE:OMND ("Optimind" or the "Company"), an emerging provider of psychedelic therapies, today provides an update on the Company's joint venture with Manitari Pharma Corporation ("Manitari Pharma"), which is 40% owned by Optimind.
安大略省多倫多-(Newsfile Corp.-2022年8月10日)-OptiMind Pharma Corp.(CSE：OMND(“OptiMind”或“公司”))，一家新興的迷幻療法供應商，今天提供了該公司與Manitari Pharma Corporation(“Manitari Pharma”)的合資企業的最新情況，OptiMind持有該公司40%的股份。
Manitari Pharma, which has submitted an application to Health Canada for a Controlled Substances Dealer's License for Psilocybin Research Purposes, has begun the process of permitting and planning the build-out of its facility in accordance with the guidance of Health Canada. Health Canada has approved Manitari Pharma's plan, pending final inspection, to install a Security Level 3 vault and grow rooms based on the Health Canada Directive on Physical Security Requirements for Controlled Substances and Drugs. A Dealer's License would permit Manitari Pharma to perform the following activities: procure controlled substances, including by import, synthesis, propagation, cultivation, and harvesting of psychedelic mushrooms for Psilocybin extraction; research and manufacture controlled substances such as Psilocybin and Psilocin; business-to-business sale of controlled substances, including by export; and sale of controlled substances via pharmacies.
Manitari Pharma已向加拿大衞生部提交了一份關於裸蓋菇素研究受控物質經銷商許可證的申請，並已開始根據加拿大衞生部的指導允許和規劃其設施的擴建過程。加拿大衞生部已經批准了Manitari Pharma的計劃，該計劃將安裝一個安全級別為3的保險庫，並根據加拿大衞生部關於管制物質和藥物物理安全要求的指令。經銷商許可證將允許Manitari Pharma進行以下活動：採購受控物質，包括通過進口、合成、繁殖、種植和收穫迷幻蘑菇以提取裸蓋菇素；研究和製造受控物質，如裸蓋菇素和裸蓋菇素；企業對企業銷售受控物質，包括通過出口；以及通過藥店銷售受控物質。
"We congratulate Manitari Pharma on being one step closer to a obtaining a Dealer's License and Optimind looks forward to continue working with Manitari Pharma as it develops treatments for qualifying patients that desperately need psychedelic-enhanced therapy to get better," commented Tomas Sipos, Chief Executive Officer at Optimind.
OptiMind首席執行官託馬斯·西波斯評論説：“我們祝賀Manitari Pharma距離獲得經銷商執照又近了一步，OptiMind期待着繼續與Manitari Pharma合作，為迫切需要迷幻增強療法才能好轉的合格患者開發治療方法。”
"I am proud to announce that Health Canada has approved Manitari Pharma's site plans for our Dealer's License. We are in the final stages of construction and expect to have our license by summers end. This will have a substantial impact in the psilocybin space and in helping secure psilocybin's use in the treatment of mental health conditions. This is vital in expanding our mission in ensuring the future mental health of First Nations and the global community at large," commented Anna Freeman, Chief Executive Officer at Manitari Pharma.
Manitari Pharma的首席執行官安娜·弗里曼評論説：“我很自豪地宣佈，加拿大衞生部已經批准了Manitari Pharma公司的經銷商執照的場地計劃。我們正處於建設的最後階段，預計我們的執照將在夏季結束。這將對裸蓋菇素領域和幫助確保裸蓋菇素用於治療精神健康方面產生重大影響。這對於擴大我們在確保第一民族和整個全球社會未來精神健康方面的使命至關重要。”
Optimind is an emerging provider of psychedelic therapy focusing on two key business verticals: its ReadyToGo Clinic in London, ON, with plans for future locations; and, Psilocybin research via its joint venture with Manitari Pharma, a First Nations focused company whose mission is to provide care to the First Nations community.
OptiMind是一家新興的迷幻療法提供商，專注於兩個關鍵的商業垂直領域：其位於倫敦的ReadyToGo診所，計劃未來的地點；以及通過與Manitari Pharma的合資企業進行裸蓋菇素研究，Manitari Pharma是一家專注於第一民族社區的公司，其使命是為第一民族社區提供護理。
Optimind offers psychedelic-assisted treatment to patients suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities.
OptiMind通過提供氯胺酮輔助治療和其他迷幻增強型心理治療方式，為患有創傷後應激障礙、焦慮、抑鬱和其他精神疾病和殘疾的患者提供迷幻輔助治療。
The joint venture with Manitari Pharma aims to help bring awareness to the benefits of psychedelic-assisted psychotherapy and advocate for federal approvals to treat depression and anxiety which remains a disproportionately large issue for the indigenous community. There is an urgent need to address the rates of depression, PTSD, anxiety, phobias and addictions in First Nations communities. Suicide rates due to mental illness among First Nations Communities, Metis, and Inuit have shown to be three times higher than anyone else in North America.1
與Manitari Pharma的合資企業旨在幫助人們認識到迷幻輔助心理治療的好處，並倡導聯邦政府批准治療抑鬱症和焦慮，這對土著社區來説仍然是一個不成比例的大問題。迫切需要解決原住民社區的抑鬱、創傷後應激障礙、焦慮、恐懼症和成癮率問題。原住民社區、梅蒂斯人和因紐特人的精神疾病自殺率比北美其他任何人都高出三倍。1
About Optimind
關於OptiMind
Optimind is an emerging provider of psychedelic therapies. We help people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities so that they can heal and live life fully. We are also partnered with developers of psilocybin-associated treatments to further expand our treatment and program offerings. For more information, visit .
OptiMind是一家新興的迷幻療法提供商。我們通過提供氯胺酮輔助治療和其他迷幻增強心理治療方式來幫助患有創傷後應激障礙、焦慮、抑鬱和其他精神疾病和殘疾的人，使他們能夠完全康復和生活。我們還與裸蓋菇素相關治療的開發商合作，進一步擴大我們的治療和計劃產品。有關更多信息，請訪問。
Caution regarding Forward-Looking Information:
有關前瞻性信息的警告：
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大證券交易所尚未對本新聞稿的充分性或準確性進行審查，也不承擔任何責任。
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19;risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
本新聞稿可能包含基於當前預期的前瞻性陳述和信息。這些聲明不應被解讀為對公司未來業績或結果的保證。這類陳述涉及已知和未知的風險、不確定因素和其他因素，可能導致實際結果、業績或成就與這類陳述所暗示的大不相同。雖然這些陳述是基於管理層的合理假設，但不能保證這些假設將被證明是正確的。我們不承擔更新或修改它們以反映新事件或新情況的責任。本公司的證券尚未根據修訂後的《1933年美國證券法》(下稱《美國證券法》)或適用的州證券法進行註冊，除非進行註冊或獲得適用的豁免，否則不得向美國境內的人或美國人提供或出售，或為美國境內的人或“美國人”的賬户或為他們的利益服務。本新聞稿不應構成出售要約或徵求購買要約，也不應在美國或任何司法管轄區出售任何此類要約、徵求或出售將是非法的證券。此外，存在已知和未知的風險因素，可能導致公司的實際結果、業績或成就與本文包含的前瞻性信息明示或暗示的任何未來結果、業績或成就大不相同，例如但不限於對獲得監管部門批准的依賴；獲得與其技術相關的知識產權的能力；有限的經營歷史；一般商業、經濟、競爭、政治、監管和社會方面的不確定性，尤其是, 與新冠肺炎有關的不確定性；與公司無法控制的因素有關的風險，包括與新冠肺炎有關的風險；與公司股票有關的風險，包括因可能或可能不在公司控制範圍內的事件而引起的價格波動；對管理層的依賴；以及行業中更多競爭對手的緊急情況。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
本文中的所有前瞻性信息都受本警示聲明的約束，公司沒有義務修改或更新任何此類前瞻性信息，也沒有義務公開宣佈對本文中包含的任何前瞻性信息的任何修改結果，以反映未來的結果、事件或發展，除非法律要求。
For more information, please contact:
如需更多信息，請聯繫：
Chief Executive Officer
Tomas Sipos
info@optimindpharma.com
首席執行官
託馬斯·西波斯
郵箱：Info@optiMindipharma.com
1
1
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問